Monitoring of antigen-specific T-cell responses is valuable in numerous conditions that include infectious diseases, vaccinations, and opportunistic infections associated with acquired or congenital immune defects. A variety of assays that make use of peripheral lymphocytes to test activation markers, T-cell receptor expression, or functional responses are currently available. The last group of assays calls for large numbers of functional lymphocytes. The number of cells increases with the number of antigens to be tested. Consequently, cells may be the limiting factor, particularly in lymphopenic subjects and in children, the groups that more often require immune monitoring. We have developed immunochemical assays that measure secreted cytokines in the same wells in which peripheral blood mononuclear cells (PBMC) are cultured. This procedure lent itself to miniaturization and automation. Lymphoproliferation and the enzyme-linked immunosorbent spot (ELISPOT) assay have been adapted to a miniaturized format. Here we provide examples of immune profiles and describe a comparison between miniaturized assays based on cytokine secretion or proliferation. We also demonstrate that these assays are convenient for use in testing antigen specificity in established T-cell lines, in addition to analysis of PBMC. In summary, the applicabilities of miniaturization to save cells and reagents and of automation to save time and increase accuracy were demonstrated in this study using different methodological approaches valuable in the clinical immunology laboratory.

Several conditions lead to defective cellular immunity. In particular, conditioning and immune ablation induced for hematopoietic stem cell transplantation (HSCT) in different hematological malignant and nonmalignant diseases result in persistent loss of T cells. Therefore, control of opportunistic infections sustained by viruses, fungi, and bacteria is lost and several months may elapse before cellular immune competence reconstitutes (1). Due to the fact that HSCT is more broadly applied, monitoring of T-cell responses specific for relevant opportunistic pathogens has become a relevant issue in the clinical immunology laboratory. Numerous tests are currently available (2) and efforts are being made to standardize and validate assays in interlaboratory cooperative studies (3). A limitation often encountered with these assays is that the number of available peripheral blood mononuclear cells (PBMC) needed to test antigens from different pathogens is insufficient. This is particularly the case with pediatric patients, due to limited blood volumes, and with lymphopenic patients. In both cases, miniaturization of assay formats results in a remarkable advantage, with reagent and cost reductions as additional benefits. Furthermore, automation that can or must associate with assay format miniaturization may contribute to assay standardization and robustness.

Since different T-cell assays can be used to characterize different T-cell functions, such as cytokine synthesis and proliferation and effector cytolytic activity (2), our goal is to miniaturize most of these assays to gain more information on the functions and specificities of responding T cells. We have been engaged in this effort since we reported on a novel assay performed in 384-well plates in which antigen-induced cytokine secretion was measured in the very same culture wells (4). This assay, termed cell enzyme-linked immunosorbent assay (cell-ELISA), was validated and further miniaturized in 1,536-well plates (5, 6). More recently, we also adapted lymphoproliferation to 384- and 1,536-well plates (7). Here we describe miniaturization of the enzyme-linked immunosorbent spot (ELISPOT) assay and comparative studies between different types of miniaturized assays.

MATERIALS AND METHODS

Media and reagents. RPMI 1640 (BioWhittaker, Verviers, Belgium) supplemented with 10 mM l-glutamine, 100 µg/ml streptomycin, 100 U/ml penicillin, and 5% autologous heparinized plasma collected after density gradient separation on lymphocyte separation medium (LSM) (Bio-Whittaker) was used for cell cultures. Fetal calf serum (FCS) was used at 5% to supplement media for maintenance of antigen-specific T-cell lines. Recombinant human interleukin 2 (IL-2) (Chiron, Emeryville, CA) was used at 30 U/ml for expansion of HIV- and cytomegalovirus (CMV)-specific T-cell lines. Phytohemagglutinin (PHA) (leukoagglutinin; Sigma-Aldrich, St. Louis, MO) was used at 5 µg/ml. Tritiated thymidine (specific activity 6.7 Ci/mmol; Amersham, United Kingdom) was used for pulsing of PBMC on day 4 for 16 h and for pulsing of T-cell lines on day 2 for 8 to 12 h. Tritiated thymidine was used at a 3-µCi/ml final concentration in medium.

Antigens. Tetanus toxoid (TT) and purified protein derivative (PPD) were purchased from Statens Serum Institut, Copenhagen, Denmark. Cytomegalovirus (CMV) lysate antigen was purchased from Microbix, Toronto, Canada. Peptides were synthesized by InBios (Naples, Italy) or by JPT (Berlin, Germany) and used as selected peptide libraries containing immunodominant CD4 and CD8 peptides (CD4 and CD8 peptide pools of CMV pp65 antigen) produced as described previously (8, 9, 10). The HLA-A2 restricted NV9 peptide from CMV pp65 was also used to test
CD8 responses (10). Final antigen concentrations were 10 μg/ml for proteins and 1 μg/ml for each peptide. Antigens were predispensed in the culture wells as 10× solutions, corresponding to 5 and 1 μl for the 384- and 1,536-well formats, and stored at −20°C for up to 12 months. Using the different assays, 200, 50, and 10 × 10^3 PBMC were seeded in each of 96-, 384-, 1,536-well plates, respectively. For fair comparison between the different formats, ELISPOT assay and lymphoproliferation results in 96- and 384-well plates were divided by 20 and by 5 in order to refer to 10 × 10^3 PBMC, the cell number seeded in 1,536-well plates.

Materials and instrumentation for miniaturized and automated processing. Cultures were performed in round-bottom 384- and 1,536-well plates (number 3671 and number 3937; Corning, Lowell, MA) or in flat-bottom plates (number 16468 and number 153613; Nunc, Roskilde, Denmark). The 96-channel Hydra II liquid handler (Matrix Technologies, Hudson, NH) was used for resuspending [3H]thymidine-pulsed cells at the end of the culture period and transferring from 384- and 1,536-well plates, respectively. For fair comparison between the different formats, ELISPOT assay and lymphoproliferation results in 96- and 384-well plates were divided by 20 and by 5 in order to refer to 10 × 10^3 PBMC, the cell number seeded in 1,536-well plates.

Donors and PBMC preparation. Healthy donors recruited among laboratory workers gave their informed consent for this study. The G. Gaslini Paediatric Institute, where the blood samples were collected, does not require specific Institutional Review Board approval if an informed consent for the in vitro study is obtained from the healthy adult donors. Peripheral blood mononuclear cells (PBMC) were obtained from heparinized venous blood separated on a conventional density gradient on LSM. After washing and counting, PBMC were suspended in complete medium containing 5% autologous heparinized plasma at 1 × 10^6/ml.

Cytokine secretion assay (cell-ELISA). The assay was set up and run as previously described in detail (4). Briefly, plates were coated with the capture anti-gamma interferon (IFN-γ) antibody, blocked, and stored at −20°C. Plates were thawed for use and received antigens and cells in duplicate. After incubation, the plates were frozen again. Before development, the thawed plates were washed and developed to reveal captured IFN-γ with a second biotinylated antibody, followed by alkaline phosphatase-conjugated streptavidin. The cell-ELISA reagents were purchased from Mabtech, Stockholm, Sweden. After washing, the PNPP phosphatase substrate (Sigma, St. Louis, MO) was added and the enzymatic reaction was carried out at room temperature for 30 min. The 384-well plate reader ELx800 (BioTek, Winooski, VE) and the 1,536-well plate reader Victor3 (PerkinElmer, Waltham, MA) were used for plate readout. The plates were read at 405 and the results were plotted against a titration

FIG 1 Representative examples of cell-ELISA. The panels show cell-ELISAs performed on healthy controls. Different individual profiles can be observed using the assay performed in 384-well plates. Tested antigens included CMV (CMV lysate, pp65 peptide mix, and immunodominant CD4 and CD8 peptides from pp65), recall antigens (TT and PPD), adenovirus hexon 5 and EBV LMP2 peptide mixes, fungal antigens (Candida albicans [Ca], Aspergillus niger [Asp niger], and Aspergillus fumigatus [Asp fum]). Adeno, adenovirus.
curve included in each plate to convert optical density (OD) into IFN-γ concentrations expressed as ng/ml.

**Miniaturized ELISPOT assay.** A conventional ELISPOT assay run in 96-well plates (8, 9) was adapted to miniaturized formats. Briefly, PBMC were cultured and stimulated in 384- and 1,536-well plates with round bottoms using 50 × 10⁶ and 10 × 10⁶ PBMC per well and antigen concentrations as described for cell-ELISA. Therefore, also in this case the PBMC numbers were reduced by 4-fold and 20-fold, respectively, in the two miniaturized formats, compared to assays run in 96-well plates with 200 × 10⁶ PBMC. Following a 20-h incubation (activation phase), cells in the wells were resuspended either manually with a multichannel pipette or automatically with a 96-channel liquid handler. At this stage, the transferred cells were collected from the 96-well plates using 50 μl of complete medium (cytokine release and capture phase). ELISPOT reagents were purchased from Mabtech. Plates were incubated for an additional 8 h and eventually washed and processed as for a conventional ELISPOT assay with a second biotinylated antibody, followed by alkaline phosphate-conjugated streptavidin and ELISPOT substrate. After development for 1 h at room temperature, spot-forming units (SFU) were blindly enumerated with a stereomicroscope. Results of duplicate wells are given as SFU per 10³ PBMC per well or the automatic dispenser. After the last stimulation cycle, following a 24-hour resting phase in the absence of IL-2 to minimize residual proliferative activity, CMV-specific CD4 T-cell lines were obtained from two healthy, seronegative subjects (11–13). Line FM was specific for HIV envelope glycoprotein gp120 and recognized the immunodominant peptide 191-205 (PAGFAILKCNNTFNY). Line GLP, specific for HIV reverse transcriptase p66, recognized the immunodominant peptide 248-262 (K DSSTVNDIQKLVGK). Briefly, PBMC at 10 × 10⁶/ml were pulsed with the relevant peptides at 1 μg/ml for 4 h at 37°C, diluted 1:5 with medium, and dispensed in 24-well plates at 2 × 10⁶/ml at 2 ml per well. IL-2 was added 4 days later. The cells were split 1:4 when the concentration exceeded 10⁶/ml. Restimulation cycles were performed every 3 weeks using 3 × 10⁶ T cells cocultured with 10⁶ autologous, 30-Gy-irradiated PBMC plus antigen in 2 ml medium. IL-2-expanded T cells were used 3 weeks after the last stimulation cycle, following a 24-hour resting phase in the absence of IL-2 to minimize residual proliferative activity. CMV-specific CD4 T-cell lines were generated with a similar protocol, based on repeated stimulation cycles with antigen-pulsed irradiated autologous PBMC, as previously reported in detail (9).

**Statistics.** Results of all assays are shown as mean values of duplicates. Student’s t test with differences defined as significant at P values of <0.01 was used for pairwise comparison of data obtained with different plate formats.

**RESULTS**

Four representative examples of specificity profiles obtained by cell-ELISA are shown in the panels of Fig. 1. Healthy donors exhibited a variety of specific responses, which included recognition of recall antigens such as TT and PPD; viral antigens from CMV, Epstein-Barr virus (EBV), and adenovirus; and fungal antigens such as Candida albicans, Aspergillus niger, and Aspergillus fumigatus.

Results from four additional donors were selected as examples of different specificity profiles obtained by lymphoproliferation in miniaturized well plates, as shown in Fig. 2. It can be noted that proliferative responses in 384- and 1,536-well plates yielded
greater cpm than those in 96-well plates. For easier comparison, results of 96-well plates were divided by 20 and results of 384-well plates were divided by 5 to refer to cpm of $10^5$/H11003$10^3$ PBMC, as for those cultured in 1,536-well plates. This trend was occasionally observed in previous experiments (7), in which proliferation in 384-well plates was compared to proliferation in 1,536-well plates. It should be noted, though, that a statistically significant difference was observed in few instances, as indicated in Fig. 2, 3, 4, 5. It is reasonable to anticipate that differences between formats may acquire statistical significance by improving the quality of replicates. Refined automation can certainly help attain this goal.

The same four donors were tested in parallel using the two assays, as shown in Fig. 3. The comparison was performed in 384- and 1,536-well plates, which were seeded with 50 and 10 $\mu$l PBMC suspension per well. Even though the results of the two assays are shown using two different units (IFN-γ as ng/ml and $[^3]$H]thymidine incorporation as cpm), the specificity profiles are similar, suggesting that both assays detect specific T cells with similar efficiency. In fact, negligible responses to TT were detected in two donors, while responses to the other tested antigens were consistently positive with both assays. Results for cell-ELISA in the two formats are similar, since IFN-γ concentrations are expected not to differ in the culture supernatants. In contrast, in the case of lymphoproliferation, total $[^3]$H]thymidine incorporation as cpm depends on the number of harvested PBMC. For an easier comparison between the two formats, cpm for 384-well plates were divided by 5 and thus referred to as $10 \times 10^3$ PBMC, as seeded in the 1,536-well plates. Sensitivity thresholds (detection of low frequencies of specific T cells) were not analyzed using PBMC but, rather, using established T-cell lines, as described later.

Four healthy donors responsive to CMV were tested with recall antigens and different CMV antigens by ELISPOT assay performed in standard 96-well plates and in miniaturized plates. Figure 4 shows the SFU counts referred to as $10 \times 10^3$ PBMC for easier comparison. Overlapping response profiles were obtained in all subjects responding to different antigenic challenges. It should be noted that higher SFU counts were consistently observed in the smaller formats than SFU in 96-well plates, with significant differences between 1,536- and 384-well plates in a few cases, as indicated in the Fig. 4 legend.

We have previously described a remarkable assay correlation using cell-ELISA in 384-well plates and ELISPOT assay in 96-well plates (G. Li Pira, F. Ivaldi, N. Starc, F. Landi, S. Rutella, F. Locatelli, N. Sacchi, G. Tripodi, F. Manca, submitted for publication). Here we provide a more extensive comparison of the two assays in which cultures were performed in the miniaturized formats of 384- and 1,536-well plates (Fig. 5). PBMC were stimulated with recall and CMV antigens to include proteins and peptides. Two CMV responders were tested. The SFU counts referred to as $10 \times 10^3$ PBMC in the two formats are shown in the left panels. Similar
profiles were obtained, with a higher efficiency for the smaller formats consistently confirmed, even though a significant difference was not observed. The ELISPOT assay profiles were similar to those of the cell-ELISA profiles depicted in the right panels.

Established T-cell lines were available in the laboratory from different donors and with different specificities. From this panel, we chose two T-cell lines specific for two HIV antigens that had been generated from seronegative, nonimmune subjects. This proved particularly convenient, as the frequency of HIV-specific T cells in PBMC from these donors, used as a source of antigen-presenting cells for T-cell stimulation, was below the detection threshold. Figure 6 shows IFN-γ production and proliferative responses of T-cell lines that were measured in parallel assays in 384- and 1,536-well plates. In the first case, each well contained 50 × 10^3 irradiated autologous PBMC plus 5,000, 500, 50, 5, and 0 specific T cells from the established lines in a 50–μl volume. In the second case, each well contained one-fifth of the same cellular reagents, corresponding to 10^4 irradiated autologous PBMC plus 1,000, 100, 10, 1, and 0 T cells from the established lines in 10 μl. The results of the two parallel assays were in agreement, independently of the format. With respect to sensitivity, it can be seen that in most cases using cell-ELISA or lymphoproliferation, between 5 and 10 specific T cells can be detected using the 384- and the 1,536-well plates. These figures correspond to actual frequencies of antigen-specific T cells from established lines.

FIG 4 ELISPOT assay in miniaturized format. Healthy donors were challenged with protein antigens (TT, PPD, CMV lysate, pp65) and with peptide antigens (pp65 peptide mix, CMV CD4 T-helper peptide pool, and CMV CD8 CTL [cytotoxic T lymphocyte] peptide pool). SFU were referred to as 10^3 PBMC for the three 96-, 384-, and 1,536-well formats. A consistent increase in SFU counts is evident with the smaller formats, indicating an increased efficiency of the miniaturized cultures. Significantly high (P < 0.01) SFU counts in the smaller formats are indicated by asterisks.

**DISCUSSION**

The reasons for running functional T-cell-specificity assays in miniaturized and automated formats have already been outlined in the introduction and discussed in depth in previous papers (2–4). The experiments we reported here address additional points and lead to several conclusions.

First of all, informative specificity profiles were obtained using different assays in miniaturized (384-well plates) and ultraminaturized (1,536-well plates) formats. This confirms that very few cells can be used, thus making it possible to test a single antigen with 50 × 10^3 or 10^4 PBMC using conventional 96-well plates.

Second, there was a good agreement between cell-ELISA and lymphoproliferation both in 384- and 1,536-well plates. This observation has already been reported with 384-well plates (7). The extension to the 1,536-well format is encouraging, since this should be the ultimate plate format to save cells and reagents, if some manipulation problems are worked out. These plates, in fact, require automated processing, as manual handling can be inaccurate and confusing, resulting in antigen mix up or poor replicates. Automated liquid dispensers, washers, and readers that...
can handle 384- and 1,536-well plates are not often present in the standard clinical immunology laboratory. Nevertheless, since their use can be extended to other miniaturized cellular immunology assays, as shown here, in addition to immunochemical and molecular biology assays, their availability should be considered in future perspectives.

It should be noted here that the assays remarkably differ in duration (1 day for cell-ELISA or ELISPOT assay, 5 days for lymphoproliferation). Therefore, a preliminary profile can be obtained by the next day, but confirmation that specific T cells carry a proliferative potential is available on day 5. The similarities between the two assays in the healthy donors we tested suggest that the lymphoproliferation assay may be dispensable, with antigen-driven production of IFN-γ reliably anticipating the proliferative response. Unfortunately, we do not know yet if this conclusion can be extended to patients with compromised cellular immunity. Particularly in patients receiving immunosuppressive drugs, cytokine secretion does not grant clonal expansion potential, and a functionally relevant discrepancy may exist between effector function and proliferative potential of memory T cells. Therefore, specific studies aimed at solving these questions need to be undertaken.

Third, the sensitivity issue was considered in light of assay miniaturization. In fact, volume reduction is simply a technicality, which can be addressed using accurate instrumentation in molecular assays that measure antibodies, other analytes, or nucleic acids. On the contrary, assay volume reduction in cellular assays must take into account the frequency of specific cells, which may be under limiting dilution conditions if reaction volumes are reduced beyond a given threshold. In fact, two parameters should be kept in mind. One is assay sensitivity, i.e., the number of specific T cells responding to a given antigenic stimulus that the can test reveal as a positive signal; the other one is the frequency of specific T cells among PBMC. In previous studies (4, 6), we have ascertained that cell-ELISA can detect IFN-γ secreted by as few as 2 to 5 specific T cells. Using limiting dilutions, we also showed that miniaturized proliferation can detect similar numbers of specific T cells (7). Here, we ran a comparative sensitivity assessment on the same T-cell samples, using established T-cell lines. This permits an accurate knowledge of the number of input-specific T cells per well, the same information being hard to gain using PBMC. As illustrated in the Results section, assuming a reasonable frequency of 0.1% T cells specific for a pathogen like CMV, one specific cell out of 1,000 PBMC can be detected. If the assay threshold is 5 specific T cells, at least 5,000 PBMC need to be cultured to detect a positive signal. To stay on the safe side, 10,000 PBMC should be seeded in the 1,536-well plate. This figure cannot be further reduced, unless higher frequencies of specific T cells are expected. A more detailed discussion on the issue of precursor frequency and liminal detection has been previously presented (14). Fourth, a comment should be made regarding the higher efficiency of cultures performed in microplates than in standard 96-well plates. In fact we observed a consistent trend for higher responses in the smaller formats (384- versus 96- and 1,536- versus 384-well plates), as if responding T cells "appreciated" the smaller culture wells. A possible explanation is that, even if PBMC concentrations were identical and thus cell densities at the bottom of flat wells would have been the same, the smaller radius in the smaller round-bottom wells increased cell density. This likely resulted in a microenvironment in which contacts between specific T cells and antigen-presenting cells (APC) were facilitated. This condition, in fact, is closer to the three-dimensional (3D) structure of a lymphoid organ than the 2D condition of a flat-bottom well. This hypothesis demands more targeted experiments, but, if
proven, it may provide additional support to the fact that the principle “the smaller the better” also applies to T-cell assays as long as miniaturization does not dilute out specific T cells to undetectable thresholds. It is also likely that PBMC resuspension allows a more efficient collection of all PBMC in the proliferation assay. Likewise, thorough dispersion of PBMC after collection of miniaturized ELISPOT assay plates before transferring to 96-well plates for cytokine capture and immunoenzymatic development may disrupt clusters of specific T cells surrounding a single APC (15) and thus reveal individual spot-forming cells rather than

FIG 6 Titration of HIV-specific T-cell lines spiked in autologous PBMC. The left panels indicate cell-ELISA results and the right panels indicate lymphoproliferation results. Upper graphs refer to an HIV gp120-specific T-cell line generated from donor FM47, while lower graphs refer to an HIV reverse transcriptase-p66-specific T-cell line generated from donor GLP61. Graded numbers of specific T cells were titrated in autologous irradiated PBMC as a source of antigen-presenting cells. Titrations were performed in 384- and 1,536-well plates. The horizontal axes indicate the percentage of T cells versus total PBMC, and the absolute numbers of specific T cells per well at the different dilutions for the two formats.

FIG 7 Titration of CMV-specific T-cell lines spiked in autologous PBMC. The left panels indicate cell-ELISA results and the right panels indicate lymphoproliferation results. Graded numbers of specific T cells obtained from CMV-specific T-cell lines generated from donors FM47 and GLP61 were titrated in autologous irradiated PBMC as a source of antigen-presenting cells. Titrations were performed in 384- and 1,536-well plates. The horizontal axes indicate the percentage of T cells versus total PBMC, and the absolute numbers of specific T cells per well at the different dilutions for the two formats.
spot-forming units. This case, as an artifact, may underestimate the actual frequency of specific T cells in standard ELISPOT assays and thus this may be an additional advantage for the two-step procedure in 384- and 1,536-well plates.

In conclusion, miniaturization and automation of assays that monitor antigen-specific T-cell immunity is feasible and can be further improved in order to save cells and reagents, to increase assay reliability and robustness, and to broaden clinical applications. These improvements result in remarkable benefits for the monitoring of specific cellular immunity (16–18) in cancer immunotherapy, immune deficiencies, and immune reconstitution associated with various conditions. In the more specific field of adoptive immune reconstitution (19), these assays may help to identify patients requiring adoptive immunotherapy before severe infections break out, select the most appropriate donor for T-cell immune reconstitution, and define successful immune restoration.

ACKNOWLEDGMENTS
This work was supported by the Italian Ministry of Health, Rome (Finalized Project 2008–2011, Establishment of a GMP-Validated Biobank), AIDS Project 2009–2013 (40H.87), and the European Union, Brussels (grant LSHB-CT-2005-018680). G.L.P. is supported by the European Union FP7 program GA (number 242146). F.M. is a consultant for grant (grant LSHB-CT-2005-018680). G.L.P. is supported by the European Commission 2008-2011, Establishment of a GMP-Validated Biobank), Establishment of a GMP-Validated Biobank, and their use as a peptide library for generation of T cells for cellular immunoconstitution. Int. Immunol. 16:635–642. http://dx.doi.org/10.1093/intimm/dx065.

REFERENCES
1. Van Burik JA, Weisdorf D. 2005. Infections in recipients of hematopoietic stem cell transplantation, p 3486–350. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious diseases. Churchill Livingstone, London, United Kingdom.
2. Kern F, Li Pira G, Gratama J, Manca F, Roederer M. 2005. Measuring antigen specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious diseases, autoimmunity and cancer. Trends Immunol. 26:477–484. http://dx.doi.org/10.1016/j.it.2005.07.005.
3. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecher HT, Melief CJM, O’Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff THM, Ottensmeier C, Pawlec G, 4 Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. 2012. T-cell assays and MIATA: the essential minimum for maximum impact. Immunity 37:1–2. http://dx.doi.org/10.1016/j.immuni.2012.07.010.
4. Li Pira G, Ivaldi F, Bottone L, Manca F. 2007. High throughput functional microdissection of pathogen-specific T-cell immunity using antigen and lymphocyte arrays. J. Immunol. Methods 326:22–32. http://dx.doi.org/10.1016/j.jim.2007.06.012.
5. Li Pira G, Ivaldi F, Dentone C, Righi E, Del Bono V, Viscoli C, Koopman G, Manca F. 2008. Evaluation of antigen specific T-cell responses with a miniaturized and automated method. Clin. Vaccine Immunol. 15:1811–1818. http://dx.doi.org/10.1128/CVI.00322-08.
6. Li Pira G, Ivaldi F, Moretti P, Tripodi G, Manca F. 2010. Validation of a miniaturized method for assessment of specific T cell immunity. J. Immunol. Methods 355:68–75. http://dx.doi.org/10.1016/j.jim.2010.02.010.
7. Li Pira G, Stark N, Conforti A, Bertaina A, Rutella S, Locatelli F, Manca F. 2012. Lymphocyte proliferation specific for recall, CMV and HIV antigens in miniaturized and automated format. J. Immunol. Methods 384:135–142. http://dx.doi.org/10.1016/j.jim.2012.07.022.
8. Li Pira G, Bottone L, Ivaldi F, Pelizzi R, Bracci L, Lozzi L, Del Galdo F, Loregian A, Palù G, Einsele H, Manca F. 2004. Identification of new Th peptides from the cytomegalovirus immunodominant protein pp65 and their use as a peptide library for generation of T cell lines for cellular immunoconstitution. Int. Immunol. 16:635–642. http://dx.doi.org/10.1093/intimm/dx065.
9. Li Pira G, Bottone L, Ivaldi F, Tagliamacco A, Fiordoro S, Ricciardi A, Barbano G, Manca F. 2005. Generation of cytomegalovirus (CMV)-specific CD4 T cell lines devoid of alloreactivity by use of a mixture of CMV-phosphoprotein 65 peptides for reconstitution of the T helper repertoire. J. Infect. Dis. 191:215–226. http://dx.doi.org/10.1086/427040.
10. Li Pira G, Ivaldi F, Bottone L, Koopman G, Manca F. 2007. Helper function of cytolytic lymphocytes: switching roles in the immune response. Eur. J. Immunol. 37:66–77. http://dx.doi.org/10.1002/eji.200636337.
11. Manca F, Habeshaw J, Dalgleish A. 1991. The naïve repertoire of human T helper cells specific for gp120, the envelope glycoprotein of HIV. J. Immunol. 146:1964–1971.
12. Manca F. 1992. Galactose receptors and presentation of HIV envelope glycoprotein to specific human T cells. J. Immunol. 148:2278–2282.
13. Li Pira G, Bottone L, Oppezzi L, Seri M, Westby M, Caroli F, Fenoglio D, Lancia F, Ferraria A, Bottone L, Vallesi MT, Kunkl AL, Dalgleish A, Romeo G, Manca F. 1998. Repertoire breadth of human CD4+ T cells specific for HIV gp120 and p66 (primary antigens) and for PPD and tetanus toxoid (secondary antigens). Hum. Immunol. 59:137–148. http://dx.doi.org/10.1016/S0198-8859(98)00004-4.
14. Li Pira G, Ivaldi F, Moretti P, Manca F. 2010. High throughput T epitope mapping and vaccine development. J. Biomed. Biotechnol. 2010:325720. http://dx.doi.org/10.1155/2010/325720.
15. Li Pira G, Ivaldi F, Manca F. 2012. Selective binding of CD4 and CD8 T-cells to antigen-presenting cells for enrichment of CMV and HIV specific T-lymphocytes. J. Immunol. Methods 376:125–131. http://dx.doi.org/10.1016/j.jim.2012.01.001.
16. Davis MM. 2008. A prescription for human immunology. Immunol. Rev. 227:835–838.
17. Hoos A, Britten CM, Huber G, O’Donnell-Tormey J. 2011. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat. Biotechnol. 29:867–870. http://dx.doi.org/10.1038/nbt.2000.
18. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. 2012. The problems and promises of research into human immunology and autoimmunity. Nat. Med. 18:48–53. http://dx.doi.org/10.1038/nm.2626.
19. Li Pira G, Kapp M, Manca F, Einsele H. 2009. Pathogen specific T lymphocytes for reconstitution of the immuno compromised host. Curr. Opin. Immunol. 21:549–556. http://dx.doi.org/10.1016/j.coi.2009.08.006.